Boxed Warning Added to Asthma, Allergy Med; EUA for Remdesivir
Inbox
| x |
|
2:56 AM (10 hours ago)
|
| |||
If you are having trouble viewing this email,
click here.
| |||||||||||||||||||
| |||||||||||||||||||
&cid=&e=5461259551b4a893fe0c287100d45c8f27d93dc212ee50c4fcc479f4fac225ef&c=proclivity_91458&pubid=202&siteid=20229&p=1)
&cid=&e=5461259551b4a893fe0c287100d45c8f27d93dc212ee50c4fcc479f4fac225ef&c=proclivity_91458&pubid=202&siteid=20229&p=3)
&cid=&e=5461259551b4a893fe0c287100d45c8f27d93dc212ee50c4fcc479f4fac225ef&c=proclivity_91458&pubid=202&siteid=20229&p=2)
Tuesday, May 5, 2020
Monday, May 4, 2020
In ‘Breakthrough' Towards Possible Treatment for Covid-19, Israel Isolates Virus Antibody
The
antibody reported as having been isolated at the IIBR is monoclonal,
meaning it was derived from a single recovered cell and is thus
potentially of more potent value in yielding a treatment.
The
antibody reported as having been isolated at the IIBR is monoclonal,
meaning it was derived from a single recovered cell and is thus
potentially of more potent value in yielding a treatment.
7 hours ago - Israel has isolated a key coronavirus antibody at its main biological research ... from COVID-19, the respiratory disease caused by the virus.
May 5, 2020 / 3:55 AM / Updated 5 hours ago
Israel isolates coronavirus antibody in 'significant breakthrough': minister
JERUSALEM
(Reuters) - Israel has isolated a key coronavirus antibody at its main
biological research laboratory, the Israeli defence minister said on
Monday, calling the step a “significant breakthrough” toward a possible
treatment for the COVID-19 pandemic.
The “monoclonal neutralising antibody” developed at the Israel Institute for Biological Research (IIBR) “can neutralise it (the disease-causing coronavirus) inside carriers’ bodies,” Defence Minister Naftali Bennett said in a statement.
The statement added that Bennett visited the IIBR on Monday where he was briefed “on a significant breakthrough in finding an antidote for the coronavirus”.
It quoted IIBR Director Shmuel Shapira as saying that the antibody formula was being patented, after which an international manufacturer would be sought to mass-produce it.
The IIBR has been leading Israeli efforts to develop a treatment and vaccine for the coronavirus, including the testing of blood from those who recovered from COVID-19, the respiratory disease caused by the virus.
Antibodies in such samples - immune-system proteins that are residues of successfully overcoming the coronavirus - are widely seen as a key to developing a possible cure.
The antibody reported as having been isolated at the IIBR is monoclonal, meaning it was derived from a single recovered cell and is thus potentially of more potent value in yielding a treatment.
Elsewhere,
there have been coronavirus treatments developed from antibodies that
are polyclonal, or derived from two or more cells of different ancestry,
the magazine Science Direct reported in its May issue.
Israel was one of the first countries to close its borders and impose increasingly stringent restrictions on movement to hamper the domestic coronavirus outbreak. It has reported 16,246 cases and 235 deaths from the illness.
The “monoclonal neutralising antibody” developed at the Israel Institute for Biological Research (IIBR) “can neutralise it (the disease-causing coronavirus) inside carriers’ bodies,” Defence Minister Naftali Bennett said in a statement.
The statement added that Bennett visited the IIBR on Monday where he was briefed “on a significant breakthrough in finding an antidote for the coronavirus”.
It quoted IIBR Director Shmuel Shapira as saying that the antibody formula was being patented, after which an international manufacturer would be sought to mass-produce it.
The IIBR has been leading Israeli efforts to develop a treatment and vaccine for the coronavirus, including the testing of blood from those who recovered from COVID-19, the respiratory disease caused by the virus.
Antibodies in such samples - immune-system proteins that are residues of successfully overcoming the coronavirus - are widely seen as a key to developing a possible cure.
The antibody reported as having been isolated at the IIBR is monoclonal, meaning it was derived from a single recovered cell and is thus potentially of more potent value in yielding a treatment.
Advertisement
Israel was one of the first countries to close its borders and impose increasingly stringent restrictions on movement to hamper the domestic coronavirus outbreak. It has reported 16,246 cases and 235 deaths from the illness.
Reporting by Dan Williams; Editing by Peter Cooney
Our Standards:The Thomson Reuters Trust Principles.
m
Coronavirus Update: COVID-19 May Raise Stroke Risk
Inbox
| x |
|
4:02 AM (17 hours ago)
|
| |||
Results of a New Hydroxychloroquine Treatment Study on 1061 Patients
COVID-19 NEWS + POLICY ANALYSIS
Key findings are:
- No cardiac toxicity was observed.
- A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%).
The authors conclude that:
“The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.”
See the complete abstract below.
The original abstract can be accessed here.
Also, the researchers made this table available.
It’s not clear when the complete study will be made available.
ABSTRACT
Background
In a recent survey, most physicians worldwide considered that hydroxychloroquine (HCQ) and azithromycin (AZ) are the two most effective drugs among available molecules against COVID-19. Nevertheless, to date, one preliminary clinical trial only has demonstrated its efficacy on the viral load. Additionally, a clinical study including 80 patients was published, and in vitro efficiency of this association was demonstrated.
Methods
The study was performed at IHU Méditerranée Infection, Marseille, France. A cohort of 1061 COVID-19 patients, treated for at least 3 days with the HCQ-AZ combination and a follow-up of at least 9 days was investigated. Endpoints were death, worsening and viral shedding persistence.
Findings
From March 3rd to April 9th, 2020, 59,655 specimens from 38,617 patients were tested for COVID-19 by PCR. Of the 3,165 positive patients placed in the care of our institute, 1061 previously unpublished patients met our inclusion criteria. Their mean age was 43.6 years old and 492 were male (46.4%). No cardiac toxicity was observed. A good clinical outcome and virological cure was obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage at completion of treatment was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < 10-2) but viral culture was negative at day 10 and all but one were PCR-cleared at day 15. A poor outcome was observed for 46 patients (4.3%); 10 were transferred to intensive care units, 5 patients died (0.47%) (74-95 years old) and 31 required 10 days of hospitalization or more. Among this group, 25 patients are now cured and 16 are still hospitalized (98% of patients cured so far). Poor clinical outcome was significantly associated to older age (OR 1.11), initial higher severity (OR 10.05) and low hydroxychloroquine serum concentration. In addition, both poor clinical and virological outcomes were associated to the use of selective beta-blocking agents and angiotensin II receptor blockers (P<0.05). Mortality was significantly lower in patients who had received > 3 days of HCQ-AZ than in patients treated with other regimens both at IHU and in all Marseille public hospitals (p< 10-2).
Interpretation
The HCQ-AZ combination, when started immediately after diagnosis, is a safe and efficient treatment for COVID-19, with a mortality rate of 0.5%, in elderly patients. It avoids worsening and clears virus persistence and contagiosity in most cases.
Source: https://www.mediterranee-infection.com/
Subscribe to:
Posts (Atom)